Literature DB >> 25943352

Feedback circuitry between miR-218 repression and RTK activation in glioblastoma.

Lijoy K Mathew1, Peiwei Huangyang2, Vera Mucaj2, Samuel S Lee1, Nicolas Skuli3, T S Karin Eisinger-Mathason2, Kevin Biju2, Bo Li2, Sriram Venneti4, Priti Lal4, Justin D Lathia5, Jeremy N Rich6, Brian Keith7, M Celeste Simon8.   

Abstract

Receptor tyrosine kinase (RTK) signaling promotes the growth and progression of glioblastoma (GBM), a highly aggressive type of brain tumor. We previously reported that decreased miR-218 expression in GBM directly promotes RTK activity by increasing the expression of key RTKs and their signaling mediators, including the RTK epidermal growth factor receptor (EGFR), phospholipase C-γ1 (PLCγ1), and the kinases PIK3CA and ARAF. However, increased RTK signaling usually activates negative feedback mechanisms to maintain homeostasis. We found that decreased miR-218 expression in GBM cells also increased the expression of genes encoding additional upstream and downstream components of RTK signaling pathways, including the RTK platelet-derived growth factor receptor α (PDGFRα) and the kinases ribosomal S6 kinase 2 (RSK2) and S6 kinase 1 (S6K1), that collectively overrode the negative feedback mechanism. Furthermore, increased RTK signaling itself suppressed miR-218 expression. Mass spectrometry and DNA pull-down identified binding of signal transducer and activator of transcription 3 (STAT3) along with the transcriptional repressor BCL2-associated transcription factor 1 (BCLAF1) directly to the miR-218 locus. These data identify previously unknown feedback loops by which miR-218 repression promotes increased RTK signaling in high-grade gliomas.
Copyright © 2015, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25943352      PMCID: PMC4437515          DOI: 10.1126/scisignal.2005978

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  36 in total

1.  Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells.

Authors:  Christopher M Furcht; Janine M Buonato; Nicolas Skuli; Lijoy K Mathew; Andrés R Muñoz Rojas; M Celeste Simon; Matthew J Lazzara
Journal:  J Cell Sci       Date:  2014-06-20       Impact factor: 5.285

2.  Analysis of protein-DNA binding by streptavidin-agarose pulldown.

Authors:  Kenneth K Wu
Journal:  Methods Mol Biol       Date:  2006

3.  REST regulates oncogenic properties of glioblastoma stem cells.

Authors:  Mohamed M Kamal; Pratheesh Sathyan; Sanjay K Singh; Pascal O Zinn; Anantha L Marisetty; Shoudan Liang; Joy Gumin; Hala Osman El-Mesallamy; Dima Suki; Howard Colman; Gregory N Fuller; Frederick F Lang; Sadhan Majumder
Journal:  Stem Cells       Date:  2012-03       Impact factor: 6.277

4.  PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.

Authors:  Hongbing Zhang; Natalia Bajraszewski; Erxi Wu; Hongwei Wang; Annie P Moseman; Sandra L Dabora; James D Griffin; David J Kwiatkowski
Journal:  J Clin Invest       Date:  2007-02-08       Impact factor: 14.808

5.  A network model of a cooperative genetic landscape in brain tumors.

Authors:  Markus Bredel; Denise M Scholtens; Griffith R Harsh; Claudia Bredel; James P Chandler; Jaclyn J Renfrow; Ajay K Yadav; Hannes Vogel; Adrienne C Scheck; Robert Tibshirani; Branimir I Sikic
Journal:  JAMA       Date:  2009-07-15       Impact factor: 56.272

6.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Authors:  Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

7.  The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer.

Authors:  J Yu; Q Cao; J Yu; L Wu; A Dallol; J Li; G Chen; C Grasso; X Cao; R J Lonigro; S Varambally; R Mehra; N Palanisamy; J Y Wu; F Latif; A M Chinnaiyan
Journal:  Oncogene       Date:  2010-07-12       Impact factor: 9.867

8.  Frequent epigenetic inactivation of the SLIT2 gene in gliomas.

Authors:  Ashraf Dallol; Dietmar Krex; Luke Hesson; Charis Eng; Eamonn R Maher; Farida Latif
Journal:  Oncogene       Date:  2003-07-17       Impact factor: 9.867

Review 9.  mTOR signaling in glioblastoma: lessons learned from bench to bedside.

Authors:  David Akhavan; Timothy F Cloughesy; Paul S Mischel
Journal:  Neuro Oncol       Date:  2010-05-14       Impact factor: 12.300

10.  miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.

Authors:  Joachim Silber; Daniel A Lim; Claudia Petritsch; Anders I Persson; Alika K Maunakea; Mamie Yu; Scott R Vandenberg; David G Ginzinger; C David James; Joseph F Costello; Gabriele Bergers; William A Weiss; Arturo Alvarez-Buylla; J Graeme Hodgson
Journal:  BMC Med       Date:  2008-06-24       Impact factor: 8.775

View more
  8 in total

Review 1.  The EGLN-HIF O2-Sensing System: Multiple Inputs and Feedbacks.

Authors:  Mircea Ivan; William G Kaelin
Journal:  Mol Cell       Date:  2017-06-15       Impact factor: 17.970

2.  miR-218 affects the ECM composition and cell biomechanical properties of glioblastoma cells.

Authors:  Małgorzata Grabowska; Konrad Kuczyński; Monika Piwecka; Alicja Rabiasz; Joanna Zemła; Paweł Głodowicz; Dariusz Wawrzyniak; Małgorzata Lekka; Katarzyna Rolle
Journal:  J Cell Mol Med       Date:  2022-06-15       Impact factor: 5.295

3.  A rationally identified panel of microRNAs targets multiple oncogenic pathways to enhance chemotherapeutic effects in glioblastoma models.

Authors:  Negar Sadeghipour; Sukumar Uday Kumar; Tarik F Massoud; Ramasamy Paulmurugan
Journal:  Sci Rep       Date:  2022-07-14       Impact factor: 4.996

4.  MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma.

Authors:  Jonathan B Bell; Frank D Eckerdt; Kristen Alley; Lisa P Magnusson; Hridi Hussain; Yingtao Bi; Ahmet Dirim Arslan; Jessica Clymer; Angel A Alvarez; Stewart Goldman; Shi-Yuan Cheng; Ichiro Nakano; Craig Horbinski; Ramana V Davuluri; C David James; Leonidas C Platanias
Journal:  Mol Cancer Res       Date:  2016-06-30       Impact factor: 5.852

Review 5.  Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma.

Authors:  Wanli Yu; Sai Liang; Chunzhi Zhang
Journal:  Neuromolecular Med       Date:  2018-09-04       Impact factor: 3.843

Review 6.  EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.

Authors:  Manfred Westphal; Cecile L Maire; Katrin Lamszus
Journal:  CNS Drugs       Date:  2017-09       Impact factor: 5.749

Review 7.  Systems and Synthetic microRNA Biology: From Biogenesis to Disease Pathogenesis.

Authors:  Hironori Matsuyama; Hiroshi I Suzuki
Journal:  Int J Mol Sci       Date:  2019-12-24       Impact factor: 5.923

8.  Aberrant expression of RSK1 characterizes high-grade gliomas with immune infiltration.

Authors:  Glaucia N M Hajj; Fernanda F da Silva; Bárbara de Bellis; Fernanda C S Lupinacci; Hermano M Bellato; Juvanier R Cruz; Claudionor N C Segundo; Igor V Faquini; Leuridan C Torres; Paulo I Sanematsu; Maria D Begnami; Vilma R Martins; Martín Roffé
Journal:  Mol Oncol       Date:  2019-12-11       Impact factor: 6.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.